Not an SEC registrant

Wake Forest University Health Sciences

Customers

3 federal agencies, 1 prime contractor

Suppliers

None disclosed

Largest customer

—

No % disclosed

Named-customer revenue

—

No estimate available

Federal obligations

$13.9M

FY2026 · USAspending.gov

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Federal contracts 3

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $13.9M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response	$10.8M	FY 2026	14	$4.3M → $15.4M → $10.8M	75A50124C00060
WAKE FOREST - ORGAN TISSUE EQUIVALENT (OTE) PLATFORM FOR VACCINE TESTING Award 75A50124C00060 on USAspending.gov ↗ Largest of 14 awards in FY2026: $3.5M obligated
Department of Defense Defense Threat Reduction Agency	$1.8M	FY 2026	13	$1.3M → $1.8M	HDTRA125C0003
IDENTIFICATION OF TEAR BIOMARKERS AS BROAD-SPECTRUM READOUTS OF CHEMICAL INJURY Award HDTRA125C0003 on USAspending.gov ↗ Largest of 13 awards in FY2026: $690.4K obligated
Department of Transportation National Highway Traffic Safety Administration	$1.3M	FY 2026	5	$1.3M → $1.3M	693JJ922F00202N
WAKE FOREST UNIVERSITY CIREN OPEN ENROLLMENT Award 693JJ922F00202N on USAspending.gov ↗ Largest of 5 awards in FY2026: $756.7K obligated

Federal subcontracts received 1

Prime contractors that subcontracted federal work to this company. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.

Company	Subawards	Fiscal year	Count	Trend	Largest subaward
The Critical Path Institute	$765.1K	FY 2025	2		75F40124C00106
SPECIFIC AIM 1: C-PATH WILL INGEST, MAP, AND CURATE THE ADTKD CLINICAL PHENOTYPING PATIENT LEVEL DATA, WHICH WILL BE COMBINED WITH URINARY/SERUM/IMAGING BIOMARKER MEASUREMENTS OF INTEREST E.G., UMOD, MUC1, EGF, FE-URIC ACID, KIDNEY FIBROSIS ETC. GENERATED BY WAKE FOREST UNIVERSITY HEALTH SCIENCES. IN ADDITION, C-PATH WILL PERFORM A LANDSCAPE ANALYSIS FOR ASSESSING THE UTILITY OF OTHER BIOCHEMICAL AND IMAGING TOOLS AND THEIR APPLICABILITY IN THE CONTEXT OF ADTKD. SUB AIM 1.2: THE SUBCONTRACTOR WILL IDENTIFY ADTKD PATIENTS, PERFORM FLUID AND IMAGING LONGITUDINAL BIOMARKER MEASUREMENTS. THE WF TEAM WILL PERFORM A COMPREHENSIVE PROSPECTIVE, LONGITUDINAL BIOBANKING COUPLED WITH SELECT BIOMARKER ANALYSIS INCLUDING FLUID AND IMAGING MARKERS. THIS EFFORT IS BASED ON THE PREVIOUS BIO-SAMPLING COLLECTION AND PROCESSING WORK WITHIN THE WF REGISTRY. Prime award 75F40124C00106 on USAspending.gov ↗ Subaward FDA-75F40124C00106-WF2024: $441.9K · Department of Health and Human Services (HHS)

Alerts are coming

Get an email when Wake Forest University Health Sciences's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.